-
Radient Pharmaceuticals Resumes Collaboration To Advance Its Onko-Sure® In Vitro Diagnostic Cancer Test In The USA
9/2/2010
Radient Pharmaceuticals Corporation (RPC) /quotes/comstock/14*!rpc/quotes/nls/rpc (RPC 0.68, +0.00, +0.03%) announced today it has resumed collaborations with Mayo Collaborative Services, Inc. to conduct a clinical study for the validation of RPC's US FDA-approved Onko-Sure(R) in vitro diagnostic (IVD) cancer test as a useful tool in colorectal cancer (CRC) recurrence and treatment monitoring.
-
Addex Drug-Candidate Effective In Alzheimer’s Disease Model
9/2/2010
Allosteric modulation company Addex Pharmaceuticals Ltd (SIX: ADXN) announced today that it has observed efficacy in a model of Alzheimer's disease using a recently discovered orally-available drug-candidate. The proprietary molecule specifically inhibits a receptor subtype called the metabotropic glutamate receptor 2 (mGluR2) via negative allosteric modulation (NAM). An Addex mGluR2 NAM is scheduled to enter Phase I clinical testing in healthy volunteers during 2011.
-
Halozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro and Aspart With rHuPH20 In Type 1 And Type 2 Diabetes
9/2/2010
Halozyme Therapeutics, Inc. (Nasdaq:
HALO) today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
-
QRxPharma Announces Interim Analysis Of Final Pivotal Phase 3 Study For MoxDuo®IR
9/2/2010
QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission. The analysis indicated the planned sample size of 140 patients has greater than 90% power to detect differences of analgesic effect, indicating there is no need to enrol additional patients.
-
Justin Hutchinson Joins Finesse Solutions As Vice-President Of Sales
9/2/2010
Finesse Solutions, LLC, a manufacturer of measurement and control solutions for life sciences process applications, announced the addition of Justin Hutchinson as its Vice President of Sales.
-
Spectrum Laboratories Introduces KrosFlo® Research IIi Tangential Flow Filtration System
9/1/2010
Spectrum Laboratories, Inc. introduces the new KrosFlo Research IIi Tangential Flow Filtration (TFF) System. This updated system—ideal for R&D scale microfiltration and ultrafiltration processing—comes with the Digital Pressure Monitor integrated into the peristaltic pump.
-
Agensys, An Affiliate Of Astellas, Announces Initiation Of Phase I Clinical Trial Of AGS-16M8F For Renal Cancer
9/1/2010
Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer.
-
Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine
9/1/2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH), for advanced development of the company's third generation anthrax vaccine candidate.
-
BTG Plc: Agreement With Nycomed US Inc.
9/1/2010
BTG plc, the specialty pharmaceuticals company, recently announces that it has signed an agreement with Nycomed US Inc. concerning the accelerated transition to BTG on 1 October 2010 of marketing rights to CroFab (Crotalidae Polyvalent Immune Fab (Ovine), an antivenom, and DigiFab (Digoxin Immune Fab (Ovine), for treating patients with life-threatening digoxin toxicity or overdose.
-
Ricerca Biosciences Successfully Completes cGMP Prep HPLC Purification
9/1/2010
Ricerca Biosciences, an integrated preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, is pleased to announce the successful completion of the purification of an active pharmaceutical ingredient (API) under current good manufacturing practices (cGMP) controls.
